Enveric Biosciences, Inc. — Q1 2022 Form 10-Q
Reporting period: Three months ended March 31, 2022; filed May 13, 2022. Enveric is an early-stage biosciences company developing psychedelic-derived drug candidates and cannabinoid-based therapies, with its principal focus on psychedelic-based treatments. It reported no revenue in the presented results.
Financial performance and position
| Metric | Q1 2022 | Q1 2021 / comparison |
|---|---|---|
| Revenue | No revenue reported | No revenue reported |
| Operating expenses | $4.80 million | $6.76 million |
| Operating loss | $4.80 million | $6.76 million |
| Net loss | $4.52 million | $3.25 million |
| Net loss per share, basic and diluted | $0.11 | $0.20 |
| Operating cash used | $4.55 million | $3.16 million |
| Cash and cash equivalents at period-end | $21.69 million | $17.36 million at Dec. 31, 2021 |
| Working capital at period-end | $20.57 million | Prior comparable value not stated here |
| Total liabilities at period-end | $7.74 million | $4.41 million at Dec. 31, 2021 |
Gross profit and operating margins are not meaningful because the company reported no revenue. The filing reports no conventional borrowings; liabilities primarily include a $3.97 million warrant liability, lease obligations and deferred taxes. The warrant liability rose from $0.65 million at year-end, principally due to warrants issued in the February offering.
Changes and cash resources
- General and administrative expense fell 57% to $2.77 million, mainly due to lower stock-based compensation and legal costs; higher salaries partly offset the decrease.
- Research and development expense increased to $1.96 million from $0.16 million, reflecting expanded product development, particularly psychedelic research.
- Net loss increased year over year despite lower operating expenses, as the prior-year period included a substantially larger noncash gain from changes in warrant fair value: $3.81 million versus $0.28 million in Q1 2022.
- Financing activities provided $9.40 million in Q1 2022. The February public offering of 20 million shares and warrants generated approximately $9.1 million net proceeds at closing; 23 million warrants were issued, exercisable at $0.55 per share. Common shares outstanding increased to 52.62 million from 32.58 million at year-end.
- Investing cash outflow was $0.51 million, primarily for laboratory equipment. Cash increased by $4.34 million during the quarter.
Outlook, risks and other notable items
- Management said available working capital was sufficient for material cash requirements for the next 12 months, while anticipating additional financing needs to carry out development plans over the following years. The company has continuing losses and an accumulated deficit of $65.26 million.
- Management disclosed insufficient unreserved authorized shares to secure an equity investment of sufficient size at the then-current share price and intended to seek stockholder approval to increase authorized shares. Approval was not assured.
- Nasdaq notified the company in February 2022 that it was below the $1.00 minimum bid price. The initial compliance period ran through August 17, 2022; failure to regain compliance could lead to delisting and make capital raising more difficult.
- After quarter-end, Enveric announced plans to spin off its cannabinoid clinical development assets into Acanna Therapeutics, subject to conditions including Nasdaq listing qualification. Acanna received $1 million in a May private placement, with up to an additional $4 million contemplated upon completion of the spin-off. Enveric guaranteed certain investor put obligations under the related terms.
- In May, the board declared a Series C preferred-stock dividend carrying special voting rights on proposals to increase authorized shares and permit a reverse split, among related matters. These proposals were linked to the company’s effort to address the Nasdaq bid-price deficiency.
- Disclosure controls were deemed ineffective at March 31, 2022 because material weaknesses in internal control over financial reporting—primarily inadequate segregation of duties—continued. Management described remediation steps, but additional measures may be needed.
- Key business risks include early-stage development and clinical/regulatory uncertainty, reliance on external funding and third parties, intellectual-property protection, foreign-currency exposure, and the possibility that research programs or the planned spin-off do not progress as expected. The filing reported no material change to risk factors in the prior annual report.
Important facts for investors to verify
- Cash burn and whether available funds continue to support management’s stated 12-month funding outlook.
- Potential dilution from the 23 million newly issued warrants, other outstanding warrants and equity awards, and any future capital raises.
- Progress on authorized-share approval and Nasdaq bid-price compliance, including any reverse split or delisting developments.
- Status and final terms of the proposed Acanna spin-off, additional private-placement funding, and Enveric’s guarantee obligations.
- Remediation of the disclosed material weakness and effectiveness of internal controls in subsequent filings.